Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies - a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group

Blood (2024) 144 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2024-204878

Published: 2024

Journal Articles

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4944.

https://doi.org/10.1182/blood-2024-207391

Published: 2024

Journal Articles

Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT

Blood (2024) 144 (Supplement 1): 2193.

https://doi.org/10.1182/blood-2024-208242

Published: 2024

Journal Articles

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Katja Sockel, Annika Neu, Maren Goeckenjan, Markus Ditschkowski, Inken Hilgendorf, Nicolaus Kröger, Francis A. Ayuk, Friedrich Stoelzel, Jan Moritz Middeke, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Matthias Fante, Daniel Wolff, Thomas Luft, Julia Winkler, Kerstin Schäfer-Eckart, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christian Junghanss, Friederike Wortmann, Susann Winter, Helga Neidlinger, Catrin Theuser, Jan Beyersmann, Martin Bornhaeuser, Sandra Schmeller, Johannes Schetelig

Blood (2024) 144 (14): 1532–1542.

https://doi.org/10.1182/blood.2024024342

Published: 2024

Includes: Supplemental data

Journal Articles

How Much Have Post-Transplant Outcomes Improved Since 2000 for Older Patients with Acute Myeloid Leukemia? a Study from the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 896.

https://doi.org/10.1182/blood-2023-179489

Published: 2023

Journal Articles

Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Relapsed/Refractory Secondary Versus De Novo AML: A Study from the ALWP/EBMT

Arnon Nagler, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Desiree Kunadt, Jan Vydra, Didier Blaise, Simona Sica, Renato Fanin, Julia Winkler, Edouard Forcade, Gwendolyn Van Gorkom, Fabio Ciceri, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 1049.

https://doi.org/10.1182/blood-2023-173636

Published: 2023

Journal Articles

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 4932.

https://doi.org/10.1182/blood-2023-180075

Published: 2023

Journal Articles

Prevention of CMV/EBV Reactivation By Double-Specific T Cells in Patients after Allogeneic Stem Cell Transplantation: Results from the Randomized Phase I/IIa Multivir-01 Study

Blood (2023) 142 (Supplement 1): 6849.

https://doi.org/10.1182/blood-2023-178273

Published: 2023

Journal Articles

Real-World Data Suggest Effectiveness of Allogeneic Mesenchymal Stromal (MSC-FFM) Cells in Ruxolitinib-Refractory Acute Graft-Versus-Host Disease

Blood (2023) 142 (Supplement 1): 4927.

https://doi.org/10.1182/blood-2023-174492

Published: 2023

Journal Articles

A Second Haploidentical Stem Cell Transplantation (HAPLO-SCT2) after Relapse from First Haplo-SCT Is Feasible and Produces Results That Are Comparable to Data Reported after Second SCT in an HLA-Matched Setting - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Giuliano Filippini Velazquez, Myriam Labopin, Johanna Tischer, Emanuele Angelucci, Alexander D. Kulagin, Piero Galieni, Arancha Bermúdez, Claude-Eric Bulabois, Nicolaus Kröger, José Luis Díez-Martin, Arnon Nagler, Christoph Schmid, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 7744–7746.

https://doi.org/10.1182/blood-2022-160229

Published: 2022

Journal Articles

Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT

Ann-Kristin Schmälter, Maud Ngoya, Jürgen Finke, Nicolaus Kröger, Friedrich Stölzel, Matthias Stelljes, Thomas Valerius, Johanna Tischer, Thomas Schroeder, Peter Dreger, Igor Wolfgang Blau, Bipin Savani, Sebastian Giebel, Jordi Esteve, Ali Bazarbachi, Arnon Nagler, Christoph Schmid, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 4799–4801.

https://doi.org/10.1182/blood-2022-163788

Published: 2022

Journal Articles

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Katja Sockel, Sandra Frank, Annika Neu, Markus Ditschkowski, Inken Hilgendorf, Mareen Goeckenjan, Friedrich Stoelzel, Jan Moritz Middeke, Nicolaus Kröger, Francis A. Ayuk, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Barbara Holler, Daniel Wolff, Thomas Luft, Wolf Roesler, Kerstin Schäfer-Eckart, Sabine Dressler, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christoph Wittke, Friederike Wortmann, Helga Neidlinger, Martin Bornhaeuser, Johannes Schetelig, on Behalf of the German Cooperative Transplant Study Group

Blood (2022) 140 (Supplement 1): 10563–10565.

https://doi.org/10.1182/blood-2022-162673

Published: 2022

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT

Blood (2022) 140 (Supplement 1): 10613–10615.

https://doi.org/10.1182/blood-2022-165472

Published: 2022

Journal Articles

Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation

Frederic Baron, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Jan Vydra, Didier Blaise, Patrizia Chiusolo, Friedrich Stölzel, Renato Fanin, Patrice Chevallier, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 7752–7753.

https://doi.org/10.1182/blood-2022-166023

Published: 2022

Journal Articles

Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation

Alessia Fraccaroli, Elena Stauffer, Katrin Koch, Klaus Hirschbühl, Stephan Breitkopf, Frank Ziemann, Heidrun Drolle, Maja Rothenberg-Thurley, Annika Maria Dufour, Klaus H. Metzeler, Michael von Bergwelt, Karsten Spiekermann, Andreas Hausmann, Christoph Schmid, Mareike Verbeek, Tobias Herold, Johanna Tischer

Blood (2022) 140 (Supplement 1): 4882–4883.

https://doi.org/10.1182/blood-2022-167299

Published: 2022

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT

Blood (2022) 140 (Supplement 1): 10547–10549.

https://doi.org/10.1182/blood-2022-162546

Published: 2022

Journal Articles

Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML - Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI

Rama Al Hamed, Myriam Labopin, Wolfgang Bethge, Arnold Ganser, Arne Brecht, Johanna Tischer, Nicolaus Kröger, Donald Bunjes, Hermann Einsele, Mareike Verbeek, Igor Wolfgang Blau, Martin Kaufmann, Eolia Brissot, Ali Bazarbachi, Christoph Schmid, Alexandros Spyridonidis, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 10455–10457.

https://doi.org/10.1182/blood-2022-170244

Published: 2022

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Blood (2021) 138 (Supplement 1): 173.

https://doi.org/10.1182/blood-2021-145167

Published: 2021

Journal Articles

Two-Year Landmark Survival Analysis after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia: An Analysis from the ALWP of the EBMT

Blood (2021) 138 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2021-149821

Published: 2021

Journal Articles

Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)

Blood (2021) 138 (Supplement 1): 3926.

https://doi.org/10.1182/blood-2021-152349

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies - a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

How Much Have Post-Transplant Outcomes Improved Since 2000 for Older Patients with Acute Myeloid Leukemia? a Study from the EBMT Acute Leukemia Working Party

Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Relapsed/Refractory Secondary Versus De Novo AML: A Study from the ALWP/EBMT

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Prevention of CMV/EBV Reactivation By Double-Specific T Cells in Patients after Allogeneic Stem Cell Transplantation: Results from the Randomized Phase I/IIa Multivir-01 Study

Real-World Data Suggest Effectiveness of Allogeneic Mesenchymal Stromal (MSC-FFM) Cells in Ruxolitinib-Refractory Acute Graft-Versus-Host Disease

Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT

Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation

Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT

Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML - Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Two-Year Landmark Survival Analysis after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia: An Analysis from the ALWP of the EBMT

Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only